

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

| OMB APPROVAL | |
|--|-----------|
| OMB Number: | 3235-0104 |
| Estimated average burden hours per response: | 0.5 |

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

| | | | |
|---|---|---|--|
| 1. Name and Address of Reporting Person* <u>BCLS II Equity Opportunities GP, LLC</u> (Last) (First) (Middle) 200 CLARENDON STREET (Street) BOSTON MA 02116 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 01/11/2024 | 3. Issuer Name and Ticker or Trading Symbol <u>Solid Biosciences Inc. [SLDB]</u> | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below) | 5. If Amendment, Date of Original Filed (Month/Day/Year) 6. Individual or Joint/Group Filing (Check Applicable Line) <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common Stock | 904,160 | I | See footnotes ⁽¹⁾⁽²⁾ |

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|--|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |

| |
|---|
| 1. Name and Address of Reporting Person* <u>BCLS II Equity Opportunities GP, LLC</u> (Last) (First) (Middle) 200 CLARENDON STREET (Street) BOSTON MA 02116 (City) (State) (Zip) |
|---|

| |
|---|
| 1. Name and Address of Reporting Person* <u>BCLS II Equity Opportunities, LP</u> (Last) (First) (Middle) 200 CLARENDON STREET (Street) BOSTON MA 02116 (City) (State) (Zip) |
|---|

Explanation of Responses:

- Represents 904,160 shares of Common Stock purchased by BCLS II Equity Opportunities, LP ("BCLS II Equity") directly from the Issuer in a private placement that closed on January 11, 2024.
- BCLS II Equity Opportunities GP, LLC ("BCLS II Equity GP") is the general partner of BCLS II Equity. As a result, BCLS II Equity GP may be deemed to share voting and

dispositive power with respect to the securities held by BCLS II Equity. BCLS II Equity GP disclaims beneficial ownership of such securities except to the extent of its pecuniary interest therein.

BCLS II EQUITY
OPPORTUNITIES GP,
LLC, By: Bain Capital
Life Sciences Investors, 01/19/2024
LLC, its ultimate manager,
By: /s/ Adam Koppel,
Title: Partner

BCLS II EQUITY
OPPORTUNITIES, LP
By: Bain Capital Life
Sciences Investors, LLC, 01/19/2024
its ultimate manager, By:
/s/ Adam Koppel, Title:
Partner

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.